Merck & Co
Latest statistics and disclosures from Merck & Co's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PSNL, MRNA, KYMR, Entrada Therapeutics, Evaxion Biotech A S America, and represent 95.42% of Merck & Co's stock portfolio.
- Reduced shares in these 2 stocks: Sutro Biopharma (-$28M), LVTX.
- Sold out of its position in LVTX.
- Merck & Co was a net seller of stock by $-30M.
- Merck & Co has $276M in assets under management (AUM), dropping by 21.16%.
- Central Index Key (CIK): 0000310158
Tip: Access up to 7 years of quarterly data
Positions held by Merck & Co consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Merck & Co
Merck & Co holds 12 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Personalis Ord (PSNL) | 40.5 | $112M | 14M | 7.96 |
|
|
| Moderna (MRNA) | 24.6 | $68M | 2.3M | 29.49 |
|
|
| Kymera Therapeutics (KYMR) | 21.7 | $60M | 772k | 77.81 |
|
|
| Entrada Therapeutics | 6.5 | $18M | 1.7M | 10.28 |
|
|
| Evaxion Biotech A/s Sponsored Ads | 2.1 | $5.8M | 1.2M | 4.77 |
|
|
| Alector (ALEC) | 2.0 | $5.5M | 3.5M | 1.56 |
|
|
| Sutro Biopharma | 1.1 | $3.2M | -89% | 272k | 11.57 |
|
| Miragen Therapeutics (VRDN) | 1.1 | $2.9M | 93k | 31.12 |
|
|
| Xilio Therapeutics (XLO) | 0.3 | $950k | 1.5M | 0.64 |
|
|
| Carisma Therapeutics (CARM) | 0.0 | $63k | 1.5M | 0.04 |
|
|
| Neuphoria Therapeutics (NEUP) | 0.0 | $39k | 10k | 3.88 |
|
|
| Tuhura Biosciences (HURA) | 0.0 | $11k | 14k | 0.76 |
|
Past Filings by Merck & Co
SEC 13F filings are viewable for Merck & Co going back to 2025
- Merck & Co 2025 Q4 filed Feb. 17, 2026
- Merck & Co 2025 Q3 filed Nov. 12, 2025
- Merck & Co 2025 Q2 filed Aug. 13, 2025